FDA 483 - Davion Inc - January 24, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Davion Inc, an OTC drug manufacturer in Newark, NJ, was cited with two observations during an FDA inspection. The inspection revealed significant deficiencies in the firm's quality control unit, including failures to investigate deviations and prevent cross-contamination, with one observation being a repeat. Additionally, the facility's buildings were found not to be maintained in a good state of repair, exhibiting chipped paint and unknown white powder in production and storage areas.
- Person
ID · 86c7c5ae-4448-4703-8de1-581835552cdf